sglt2 inhibitors vs glp-1 Cardiovascular benefits of and receptor agonists through effects on mitochondrial function and oxidative stress GLP-1 receptor agonists vs. SGLT-2

This suggests the pain relief observed in the trial is not purely a downstream consequence of losing weight but may involve a separate pathway

Semaglutide: Through once-weekly dosing, this long-acting GLP-1 lowers blood glucose and supports sustained weight loss

Pasternak B et al

When might Contrave suit someone better than a GLP-1, in the article's framing

Participants should always follow the dose-escalation schedule provided by their trial team and should not attempt to self-adjust their dose

results varied across dose groups and this context is important when interpreting the data GI side effects were the most common adverse events, consistent with the GLP-1 class, and were predominantly mild to moderate in severity, declining over time Small increases in heart rate and gallbladder-related events were also observed, consistent with class effects The trial was of limited duration